Presentation is loading. Please wait.

Presentation is loading. Please wait.

That Patient Who Will Not Quit – A New Treatment Option April 18, 2007 Michael C. Fiore, MD, MPH Professor of Medicine Director, Center for Tobacco Research.

Similar presentations


Presentation on theme: "That Patient Who Will Not Quit – A New Treatment Option April 18, 2007 Michael C. Fiore, MD, MPH Professor of Medicine Director, Center for Tobacco Research."— Presentation transcript:

1 That Patient Who Will Not Quit – A New Treatment Option April 18, 2007 Michael C. Fiore, MD, MPH Professor of Medicine Director, Center for Tobacco Research and Intervention University of Wisconsin School of Medicine and Public Health

2 Over the last year, I have served as an investigator in research studies at the University of Wisconsin that were funded by Pfizer. In 1998, I was appointed to a named Chair made possible by an unrestricted gift to UW from GlaxoWellcome to the University of Wisconsin. Disclosure Statement

3 Case Study Mr. and Mrs. S Both late 60s Both NIDDM Both Hyperlipidemia Both BMIs over 35 Both smoke more than a ppd and have tried to quit many times

4 A New Quit Attempt Varenicline Quit Line

5 Varenicline Approved by FDA in May, 2006 Marketed as Chantix A non-nicotine medication A selective  4  2 Nicotinic Acetylcholine Receptor Partial Agonist

6 Varenicline: A Highly Selective  4  2 Receptor Partial Agonist Chantix Chantix is an  4  2 nicotinic receptor partial agonist, a compound with dual agonist and antagonist activities. This is believed to result in both a lesser amount of dopamine release from the VTA at the nAcc as well as the prevention of nicotine binding at the  4  2 receptors Nicotine Binding of nicotine at the  4  2 nicotinic receptor in the Ventral Tegmental Area (VTA) is believed to cause release of dopamine at the Nucleus Accumbens (nAcc)

7 Varenicline Efficacy Data

8 Varenicline Phase 3 Studies: Efficacy Measurements: CO-Confirmed 4-Wk Continuous Abstinence Rates Wks 9-12

9 Point Prevalence Outcome

10 Varenicline: Most Common Adverse Events From 12-Week Fixed-Dose, Placebo-Controlled Studies

11 Varenicline – Prescribing Information Start varenicline one week before the quit date for maximum effectiveness Recommended treatment is 12 weeks: – Days 1-3………..1 pill (0.5 mg) per day – Days 4-7………..1 pill (0.5 mg) twice a day (am & pm) – Day 8-end………1 pill (1 mg) twice a day (am & pm) An additional course of 12 weeks for maintenance can be considered

12 Treatment Counseling – The Wisconsin Tobacco Quit Line at 1-800-QUIT-NOW. – It’s free, confidential, and non-judgmental. – Callers are 4 times more likely to quit than those who try to quit cold turkey. – Services are available in virtually any language.

13 Designed to help employees at the University of Wisconsin Hospital and Clinics quit. A UWHC Employee Program 608-438-4517

14 UW-CTRI Outreach Specialist Southern Region- Madison Tricia Brein, MS UW-CTRI 1930 Monroe St, Suite 200 Madison, WI 53711 608-265-4860 Fax: 608-265-3102 trb@ctri.medicine.wisc.edu

15 15 www.ctri.wisc.edu


Download ppt "That Patient Who Will Not Quit – A New Treatment Option April 18, 2007 Michael C. Fiore, MD, MPH Professor of Medicine Director, Center for Tobacco Research."

Similar presentations


Ads by Google